Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Antisense oligonucleotide-mediated alternative splicing has great potential for treatment of Duchenne muscular dystrophy (DMD) caused by mutations within nonessential regions of the dystrophin gene. We have recently shown in the dystrophic mdx mouse that exon 23, bearing a nonsense mutation, can be skipped after intramuscular injection of a specific 2′- O -methyl phosphorothioate antisense oligoribonucleotide (2OMeAO). This skipping created a shortened, but in-frame, transcript that is translated to produce near-normal levels of dystrophin expression. This expression, in turn, led to improved muscle function. However, because DMD affects muscles body-wide, effective treatment requires dystrophin induction ideally in all muscles. Here, we show that systemic delivery of specific 2OMeAOs, together with the triblock copolymer F127, induced dystrophin expression in all skeletal muscles but not in cardiac muscle of the mdx dystrophic mice. The highest dystrophin expression was detected in diaphragm, gastrocnemius, and intercostal muscles. Large numbers of fibers with near-normal level of dystrophin were observed in focal areas. Three injections of 2OMeAOs at weekly intervals enhanced the levels of dystrophin. Dystrophin mRNA lacking the targeted exon 23 remained detectable 2 weeks after injection. No evidence of tissue damage was detected after 2OMeAO and F127 treatment either by serum analysis or histological examination of liver, kidney, lung, and muscles. The simplicity and safety of the antisense protocol provide a realistic prospect for treatment of the majority of DMD mutations. We conclude that a significant therapeutic effect may be achieved by further optimization in dose and regime of administration of antisense oligonucleotide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Very mild muscular dystrophy associated with the deletion of 46% of dystrophin
England, S. B., Nicholson, L. V. B., Johnson, M. A., Forrest, S. M., Love, D. R., Zubrzycka-Gaarn, E. E., Bulman, D. E., Harris, J. B., & Davies, K. E. (1990) · Nature · doi:10.1038/343180a0 · Cited by 623
Systemic delivery of genes to striated muscles using adeno-associated viral vectors
Gregorevic, P., Blankinship, M. J., Allen, J. M., Crawford, R. W., Meuse, L., Miller, D. G., Russell, D. W., & Chamberlain, J. S. (2004) · Nature Medicine · doi:10.1038/nm1085 · Cited by 620
Expression of full-length utrophin prevents muscular dystrophy in mdx mice
Tinsley, J., Deconinck, N., Fisher, R., Kahn, D., Phelps, S., Gillis, J.-M., & Davies, K. (1998) · Nature Medicine · doi:10.1038/4033 · Cited by 615
Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.
Dominski, Z., & Kole, R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8673 · Cited by 426
Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse
Lu, Q. L., Mann, C. J., Lou, F., Bou-Gharios, G., Morris, G. E., Xue, S.-A., Fletcher, S., Partridge, T. A., & Wilton, S. D. (2003) · Nature Medicine · doi:10.1038/nm897 · Cited by 398
Self-citationAntisense-induced exon skipping and synthesis of dystrophin in the mdx mouse
Mann, C. J., Honeyman, K., Cheng, A. J., Ly, T., Lloyd, F., Fletcher, S., Morgan, J. E., Partridge, T. A., & Wilton, S. D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.42 · Cited by 388
Self-citationInhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides.
Goodchild, J., Agrawal, S., Civeira, M. P., Sarin, P. S., Sun, D., & Zamecnik, P. C. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.15.5507 · Cited by 229
Lu, Q. L., Morris, G. E., Wilton, S. D., Ly, T., Artem'yeva, O. V., Strong, P., & Partridge, T. A. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.148.5.985 · Cited by 197
Self-citationNon-viral gene delivery in skeletal muscle: a protein factory
Lu, Q. L., Bou-Gharios, G., & Partridge, T. A. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301874 · Cited by 184
Self-citation
Cited by
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M. E., Bourke, J., Wells, D. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60756-3 · Cited by 878
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Rinaldi, C., & Wood, M. J. A. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.148 · Cited by 788
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051
van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073108 · Cited by 781
Lee, K., Conboy, M., Park, H. M., Jiang, F., Kim, H. J., Dewitt, M. A., Mackley, V. A., Chang, K., Rao, A., Skinner, C., et al. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0137-2 · Cited by 755
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 545
Splice-switching antisense oligonucleotides as therapeutic drugs
Havens, M. A., & Hastings, M. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw533 · Cited by 538
Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy
McGreevy, J. W., Hakim, C. H., McIntosh, M. A., & Duan, D. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.018424 · Cited by 512
Alter, J., Lou, F., Rabinowitz, A., Yin, H., Rosenfeld, J., Wilton, S. D., Partridge, T. A., & Lu, Q. L. (2006) · Nature Medicine · doi:10.1038/nm1345 · Cited by 494
Self-citationSingh, N. K., Singh, N. N., Androphy, E. J., & Singh, R. N. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1333-1346.2006 · Cited by 454
Gene therapy progress and prospects: non-viral gene therapy by systemic delivery
Li, S.-D., & Huang, L. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302838 · Cited by 391
Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon
Hua, Y., Vickers, T. A., Baker, B. F., Bennett, C. F., & Krainer, A. R. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050073 · Cited by 340
Applying nonsense-mediated mRNA decay research to the clinic: progress and challenges
Kuzmiak, H. A., & Maquat, L. E. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.05.005 · Cited by 253
Wu, B., Moulton, H. M., Iversen, P. L., Jiang, J., Li, J., Li, J., Spurney, C. F., Sali, A., Guerron, A. D., Nagaraju, K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805676105 · Cited by 236
Self-citationCell penetrating peptides: overview and applications to the delivery of oligonucleotides
Said Hassane, F., Saleh, A. F., Abes, R., Gait, M. J., & Lebleu, B. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0186-0 · Cited by 211
McClorey, G., Moulton, H. M., Iversen, P. L., Fletcher, S., & Wilton, S. D. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302800 · Cited by 207
Polymersome delivery of siRNA and antisense oligonucleotides
Kim, Y., Tewari, M., Pajerowski, J. D., Cai, S., Sen, S., Williams, J., Sirsi, S., Lutz, G., & Discher, D. E. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.10.020 · Cited by 184
“Careful selection of the skipped exons can yield a truncated, but in frame, gene product that provides sufficient rescue of function [9,10].”
Antisense oligonucleotides: treating neurodegeneration at the level of RNA
DeVos, S. L., & Miller, T. M. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0194-5 · Cited by 164
“Dystrophin-splicing ASOs were developed and tested in DMD transgenic mice, resulting in significantly improved muscle function and restoration of dystrophin protein levels [7, 104].”
BackgroundAntisense Drug Discovery and Development
Yamamoto, T., Nakatani, M., Narukawa, K., & Obika, S. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.2 · Cited by 158
Treatment of human disease by adeno-associated viral gene transfer
Warrington, K. H., & Herzog, R. W. (2006) · Human Genetics · doi:10.1007/s00439-006-0165-6 · Cited by 155
“…strategy has been proposed for treating DMD with AAV gene therapy designed to perturb nuclear RNA processing in order to rescue the transcript by skipping mutant exons (Aartsma-Rus et al. 2004; Gebski et al. 2003; Goyenvalle et al. 2004; Lu et al. 2003a, 2005; Matsuo 2002; Wilton et al. 1997).”
MethodSkeletal Muscle Degenerative Diseases and Strategies for Therapeutic Muscle Repair
Tabebordbar, M., Wang, E. T., & Wagers, A. J. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132450 · Cited by 79
“2′OMPs designed to target exon 23 of the DMD gene in mdx mice restored dystrophin expression in skeletal muscle when injected intramuscularly (233) or intravascularly (234).”
BackgroundMollanoori, H., Rahmati, Y., Hassani, B., Havasi Mehr, M., & Teimourian, S. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2019.12.007 · Cited by 32
Metadata
- Authors
- Lu, Q. L., Rabinowitz, A., Chen, Y. C., Yokota, T., Yin, H., Alter, J., Jadoon, A., Bou-Gharios, G., & Partridge, T.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2004-12-17
- Volume
- 102
- Issue
- 1
- Pages
- 198-203
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1996860050
- Cited by
- 402
- References
- 20
- FWCI
- 7.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.